Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been adopted as the standard of care for non-small cell lung cancer (NSCLC) patients harboring EGFR sensitizing mutations. Besides the two common mutations exon 19 deletion and L858R, which together comprise a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yao, Shen, Ji-Qiao, Shao, Lin, Chen, Yan, Lei, Lei, Wang, Jia-Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462190/
https://www.ncbi.nlm.nih.gov/pubmed/34621884
http://dx.doi.org/10.12998/wjcc.v9.i27.8220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462190/
https://www.ncbi.nlm.nih.gov/pubmed/34621884
http://dx.doi.org/10.12998/wjcc.v9.i27.8220

Ejemplares similares